If you are just not discovering the earning potential of Amazon.com Inc. (AMZN), than you have a lot of reason to be excited..
And I say that because I am still seeing a huge amount of upside ahead.
Let’s start with item number 1. When we spoke on January 24, I noted that much of Wall Street was cool to the stock for years.
But I have a more current example of a high profile stock “guru” who missed the boat completely. And not that long ago.
When AMZN crossed the $1,000 mark on May 31, 2017, Jim Cramer, went on TV to bash the stock. The host of CNBC’s Mad Money said “psychologically” $1,000 is a lot to pay for a stock he felt was getting ahead of itself.
The stock has more than doubled since then, reaching a closing high of $2,021.
Please don’t think I’m taking delight in watching folks lose money. Well unless it’s those “geniuses” on Wall Street. Just saying…
Here’s the simple truth. If folks don’t listen to me, I can’t help them.
I have said for many years now that the average retail investor should avoid buying high-tech initial public offerings (IPOs) when they first start trading. When you buy at the open, you really risk losing your hard earned money.
It’s much better to wait a little more than six months from the open. That’s when insiders can sell, an event that usually means a big drop in price.
Had you followed that advice with a savvy cloud provider I’ve recommended, you could have made 863% in just a tad more than five years.
But if you bought at the open, you risked losing more than half your capital.
I’ve been writing about 5G high-speed cellular networks for more than five years now, and I couldn’t be more excited for what’s ahead in 2020.
Sure, 2019 saw a fair amount of progress in rolling out this advanced new platform. The nextgen mobile network is available in a few markets.
But we have a big catalyst coming in fall 2020. That’s when Apple Inc. (AAPL) unveils a new iPhone that’s 5G native.
Don’t underestimate the importance of this move. Apple sets the standard for the rest of the sector.
5G will be important for the entire tech ecosystem in the year ahead, and it’s just one major catalyst that investors should track. There are key developments with chip stocks and beaten-down software and cloud players that all matter to your portfolio.
Editor's Note: These past few weeks, I've been updating you on a special research project that I've been working on. Well, now, my research is finished and it was well worth the effort. I've pinpointed a tiny company, currently trading for...
By now, I think it’s safe to say that Jim Cramer was dead wrong.
And I was right on the money.
Here’s the thing. I remember very clearly the day that Amazon.com Inc. (AMZN) crossed the $1,000 mark on May 31, 2017.
Cramer, the host of CNBC’s Mad Money looked at the price and slammed it. He said that “psychologically” $1,000 is a lot to pay for a stock he felt was getting ahead of itself.
As the saying goes, that was then and this is now.
No doubt, the tech leader hit a rough patch late last year with the rest of the market. And it has come under fire recently as part of the Big Tech backlash.
Yet, below-expected earnings reports for Q2 and Q3 of this year could only pull Amazon down into the $1,700 range, still far above what Cramer was worrying about.
Not only that, but the “King of E-commerce” is well positioned for another historic moment. It’s roughly 15% away from having a $1 trillion market cap, and most of that would just be regaining lost ground
And today, you’ll see why I still firmly believe the stock will hit at least $3,000 a share – and likely much, much more than that…
You could forgive drug and biotech executives for having a bad case of target fixation.
After all, they do work in a field that is filled with time-consuming and expensive headaches.
Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.
The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.
With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.
And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.
It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months…
Tension in the Middle East and the South China Sea… a political mess at home… sky-high stock prices.
And here’s something else to worry about…
On Nov. 1, a Wall Street Journal headline warned about the “Consumer Confidence Conundrum.”
Here’s the worry: According to WSJ writer Chris Dieterich and the folks he talked, because consumer confidence is at its highest level since December 2000, it’s time to “add this to the list of reasons investors ought to be getting nervous.”
The reason: It may signal the bull market is coming to an end.